Avalo Therapeutics, Inc.

AVTX

Explore Our Financial Data > Companies > Avalo Therapeutics, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
AVTX
CIK0001534120
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address540 GAITHER ROAD, SUITE 400, ROCKVILLE, MD, 20850
Website avalotx.com
Phone410-522-8707
CEOGarry A. Neil
Employees40

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$59,000.00
Pre-Tax Income$-84.57 million
Net Income$-84.74 million
Net Income to Common$-84.74 million
EPS$-4.21
View All
Balance Sheet
Cash$24.99 million
Assets$99.88 million
Liabilities$31.56 million
Common Equity$68.32 million
Liabilities & Equity$99.88 million
View All
Cash Flow Statement
Net Income$-84.74 million
Cash From Operating Activities$-59.69 million
Cash From Investing Activities$-56.22 million
Cash From Financing Activities$15.99 million
Change in Cash$-99.92 million
View All
Calculations
NOPAT$-55.41 million
EBITDA$-89.15 million
Price to EarningsN/A
Price to Book$13.65
ROE-88.76%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 programCompleted public offering of equity securities for gross proceeds of $431.3 million Cash, cash equivalents, and short-term investments of $82 million as of March 31, 2026, not including the subsequent financing WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical st

Article Link

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.

Article Link

Avalo shares spike on skin drug data; BioNTech to cut staff

Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.

Article Link

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced the pricing of its underwritten public offering of 19,730,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,400,000 shares of common stock. The shares of common stock are being sold at a publ

Article Link

Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants

Article Link